PDS1000 ml

PDS are sterile dialysate fluids used to perform peritoneal dialysis (PD), a form of renal replacement therapy. They are instilled into the peritoneal cavity through a surgically placed peritoneal catheter, allowed to dwell, and then drained, removing waste products, excess fluid, and correcting electrolyte/acid-base imbalances via the peritoneal membrane.

Established / guideline-supported uses

• End-stage renal disease (ESRD): PDS are indicated as a mode of chronic renal replacement therapy in patients with ESRD who require dialysis, performed as continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD) using a cycler, under nephrologist supervision.
• Acute kidney injury (AKI): In selected clinical settings (e.g., where hemodialysis is unavailable, hemodynamically unstable patients, or resource-limited settings), PDS may be used to provide acute renal replacement therapy, per guideline-supported practice (e.g., KDIGO).

Off-label / historical use

• PDS have historically been used off-label as an adjunct for the removal of certain dialyzable toxins/poisons in acute poisoning, although this practice has been largely superseded by hemodialysis and hemoperfusion and is rarely used today.

The specific formulation, osmotic agent (dextrose, icodextrin, or amino acids), and exchange regimen are individualized by the treating nephrologist based on the patient's fluid, solute, and metabolic needs.

Peritoneal Dialysis solutions are sterile, pyrogen-free aqueous solutions supplied in flexible plastic bags for intraperitoneal administration. Composition varies by product and strength, but typically includes:

• Osmotic/ultrafiltration agent: dextrose (glucose) monohydrate, commonly available in 1.5%, 2.5%, and 4.25% concentrations; or icodextrin 7.5% (a glucose polymer) for extended dwells; or amino acids 1.1% in specialized formulations.
• Electrolytes: sodium chloride, calcium chloride, magnesium chloride.
• Buffer: lactate and/or bicarbonate, to correct metabolic acidosis associated with renal failure.
• Water for injection as the vehicle, with pH adjusted using hydrochloric acid/sodium hydroxide as needed.

Some presentations are supplied as two-chamber bags in which the buffer and electrolyte/dextrose components are kept separate until immediately before use to maintain stability.

PDS are sterile dialysate solutions designed for use in peritoneal dialysis, a treatment that uses the patient's own peritoneal membrane as a semi-permeable filtering surface. The solution is infused into the peritoneal cavity via a surgically implanted catheter, left to dwell for a prescribed period, and then drained out, carrying with it metabolic waste products, excess fluid, and electrolytes that the failing kidneys can no longer clear.

PDS are available in different osmotic strengths and buffer systems to allow the prescribing nephrologist to individualize fluid removal (ultrafiltration) and solute clearance according to each patient's clinical status. They are used both in continuous ambulatory peritoneal dialysis (manual exchanges performed by the patient or caregiver) and automated peritoneal dialysis (performed overnight using a cycler device).

PDS belong to the therapeutic class of renal replacement therapy solutions / peritoneal dialysis fluids, used in the management of end-stage renal disease and, in selected cases, acute kidney injury.

Mechanism of solute and fluid removal

Peritoneal Dialysis solutions work through two complementary physiological processes across the peritoneal membrane:

• Diffusion: Uremic waste products (urea, creatinine, uric acid) and excess electrolytes (notably potassium) move from the blood in the peritoneal capillaries, across the peritoneal membrane, into the dialysate, down their concentration gradients.
• Osmosis (ultrafiltration): The osmotic agent in the dialysate (dextrose or icodextrin) creates an osmotic gradient that draws excess plasma water across the peritoneal membrane into the dialysate, which is then drained off. Higher dextrose concentrations (e.g., 4.25%) produce greater ultrafiltration than lower concentrations (e.g., 1.5%). Icodextrin produces sustained ultrafiltration over long dwell times through colloid osmosis.

The lactate (or bicarbonate) buffer in the solution is absorbed systemically and metabolized, helping to correct the metabolic acidosis of renal failure. Calcium and magnesium content are adjusted to help maintain mineral homeostasis in dialysis patients.

PDS are administered intraperitoneally via a surgically placed peritoneal dialysis catheter, using strict aseptic ("no-touch") technique for every exchange to reduce the risk of peritonitis. Key steps include:

• Hand hygiene and use of a face mask during connections/disconnections as trained.
• Visual inspection of the bag for leaks, cloudiness, discoloration, or particulate matter before use; the solution should be warmed to body temperature using a dedicated warming device (never a microwave) prior to infusion.
• Connection to the catheter, instillation (fill), a prescribed dwell period, and drainage, following the exact sequence and exchange schedule set by the nephrology team.
• Automated peritoneal dialysis uses a cycler device to perform multiple exchanges automatically, typically overnight.

Patients and caregivers should be formally trained by a dialysis nurse before performing exchanges independently.

Clinically significant interactions relevant to PDS include:

• Icodextrin-containing solutions and blood glucose monitoring: Icodextrin is metabolized to maltose, which can cause falsely elevated blood glucose readings on glucose meters that use the glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ) or GDH-FAD methods. This can mask true hypoglycemia in patients using insulin or other glucose-lowering therapy; a glucose-specific (glucose oxidase or hexokinase) monitoring method should be used in patients on icodextrin-based PDS.
• Medications added directly to the dialysate (e.g., heparin, insulin, or antibiotics, as prescribed by the physician): compatibility and stability with the specific dialysate formulation must be verified before admixture, as some drugs may be inactivated or precipitate in certain dialysate compositions.
• Diuretics and antihypertensives: Because PDS actively remove fluid and electrolytes, concurrent diuretic or antihypertensive therapy may require dose adjustment to avoid additive hypotension or electrolyte disturbances; monitor closely.

Adverse effects associated with the use of PDS relate mainly to the dialysis procedure itself and to the composition of the dialysate:

• Peritonitis: the most common serious complication; presents with abdominal pain, cloudy effluent, and fever (see Precautions and Warnings).
• Exit-site or tunnel infection of the catheter.
• Hyperglycemia with dextrose-based solutions, particularly in patients with diabetes.
• Fluid and electrolyte disturbances: hypokalemia, hypernatremia or hyponatremia, fluid overload, or dehydration/excessive ultrafiltration.
• Abdominal discomfort, bloating, or pain during fill or dwell.
• Protein and amino acid loss across the peritoneal membrane with long-term use, which may contribute to malnutrition.
• Hernia (inguinal, umbilical, or incisional) related to sustained increased intra-abdominal pressure.
• Weight gain and dyslipidemia from long-term dextrose (calorie) absorption.
• Encapsulating peritoneal sclerosis (rare, but serious complication of long-term peritoneal dialysis).

Data specifically evaluating PDS in pregnancy are limited. Pregnancy in a patient with ESRD is high-risk and requires close, coordinated management between nephrology and maternal-fetal medicine specialists. When peritoneal dialysis is the chosen or necessary renal replacement modality during pregnancy, PDS should be used only under direct nephrologist guidance, with the treatment intensity (exchange frequency/volume) adjusted to meet the increased metabolic and fluid demands of pregnancy; use only if clearly needed and if the benefit of continued renal replacement therapy justifies the potential risks. There is no well-established formal pregnancy category for this product class.

There is no specific contraindication to breastfeeding based on the dialysate itself, as it is not systemically administered like an oral or injectable drug in the conventional sense; however, breastfeeding mothers on peritoneal dialysis should be managed and monitored by their nephrology team, given the overall complexity of dialysis during lactation.

Peritonitis

Peritonitis is the most important and serious complication associated with the use of PDS and peritoneal dialysis in general. Strict aseptic ("no-touch") technique must be used for every exchange and catheter connection/disconnection. Patients should be trained to recognize early warning signs — cloudy dialysate effluent, abdominal pain, fever, or nausea — and to seek prompt medical attention, as untreated peritonitis can lead to catheter loss or, rarely, sepsis.

Hyperglycemia

Dextrose-based PDS are absorbed systemically and can raise blood glucose, particularly in patients with diabetes mellitus; blood glucose should be monitored regularly and insulin or other glycemic therapy adjusted as needed.

Fluid and electrolyte imbalance

Excessive or insufficient ultrafiltration can lead to dehydration/hypotension or fluid overload/hypertension, respectively. Serum electrolytes (particularly potassium, sodium, calcium, and magnesium) should be monitored periodically.

Catheter-related complications

Exit-site and tunnel infections, catheter malposition, and mechanical drainage problems can occur and require prompt evaluation.

Training and supervision

PDS must only be used after formal training by qualified dialysis staff, and patients require ongoing periodic medical and laboratory follow-up with their nephrology team.

Use with caution in

Patients with severe hepatic impairment or conditions predisposing to lactic acidosis (when using lactate-buffered solutions), significant hyperlipidemia (with prolonged dextrose exposure), and those with abdominal hernias.

Excessive dwell volume, prolonged dwell time, or use of an inappropriately high-strength PDS can lead to excessive ultrafiltration, resulting in dehydration, hypotension, and electrolyte disturbances (including hypokalemia and hyponatremia). Conversely, retained dialysate (incomplete drainage) or an inappropriately low-strength solution can contribute to fluid overload, hypertension, and shortness of breath.

If signs of excessive fluid loss (dizziness, hypotension, cramping) or fluid overload (swelling, breathlessness) occur, the patient or caregiver should stop the current exchange as instructed, drain the abdomen if appropriate, and seek immediate medical attention or contact the nephrology/dialysis care team or emergency services promptly. Do not attempt to self-adjust the dialysis prescription without medical guidance.

Store PDS at room temperature (below 30°C) in the original outer packaging until ready for use; protect from freezing and from direct sunlight/excessive heat. Do not use if the overwrap or bag is damaged, if the solution is cloudy, discolored, or contains visible particles, or if the bag shows any sign of leakage. Warm the solution to body temperature using a dedicated dialysis fluid warmer (never a microwave) immediately before use. Keep out of reach of children.

Pediatric use

PDS are used in children with ESRD requiring renal replacement therapy, with fill volumes individualized by body surface area and closely supervised by a pediatric nephrologist; safety and dosing in neonates and very young infants should be individualized with specialist input.

Elderly patients

PDS can be used in elderly patients with ESRD; dose (fill volume, exchange frequency) should be individualized based on body size, comorbidities, and tolerance, with close monitoring for fluid balance and infection.

Diabetic patients

Dextrose-based PDS increase glucose absorption; glycemic control should be monitored closely and antidiabetic therapy adjusted as needed (see Precautions and Warnings).

Hepatic impairment

Use lactate-buffered PDS with caution in patients with severe hepatic impairment or conditions with reduced lactate metabolism, due to a risk of lactic acidosis; bicarbonate-buffered formulations may be preferred in such patients.

Pregnancy

See Pregnancy and Lactation — use only under direct nephrologist and maternal-fetal medicine supervision.

PDS are typically used long-term/indefinitely in patients with ESRD, for as long as peritoneal dialysis remains the chosen and clinically appropriate renal replacement modality, or until the patient transitions to hemodialysis or receives a kidney transplant. In acute kidney injury, treatment continues until renal function recovers sufficiently or an alternative modality is selected, as determined by the treating nephrologist.

Most PDS are supplied ready-to-use and do not require reconstitution. Certain formulations (e.g., bicarbonate/lactate-buffered two-chamber bags) are supplied with the components separated by a frangible seal to maintain chemical stability during sterilization; immediately before use, the seal between the two chambers must be broken and the compartments thoroughly mixed to form the final solution, following the manufacturer's instructions, before warming and administration.

Peritoneal Dialysis solutions fall under the drug/product class of peritoneal dialysis solutions (renal replacement therapy fluids), which includes dextrose-based, icodextrin-based, and amino-acid-based dialysate formulations.

Peritoneal Dialysis solutions act by creating an osmotic gradient (via dextrose, icodextrin, or amino acids) across the peritoneal membrane that draws excess fluid from the blood into the peritoneal cavity (ultrafiltration), while uremic toxins and excess electrolytes diffuse from the blood into the dialysate down their concentration gradients (diffusion). The lactate or bicarbonate buffer in the solution corrects the metabolic acidosis of renal failure once absorbed and metabolized. The used dialysate, now containing removed waste products, fluid, and electrolytes, is subsequently drained from the peritoneal cavity.

PDS are used in pediatric patients with end-stage renal disease who require renal replacement therapy, with fill volume individualized based on body surface area (commonly starting around 800-1,100 mL/m² and titrated as tolerated) and dwell/exchange schedules tailored by a pediatric nephrologist. Safety and efficacy in neonates and infants have not been as extensively established as in older children and adults, and use in this age group should be individualized with specialist pediatric nephrology input and close monitoring.